Resumen

El propósito de este estudio clínico es determinar si apixabán es más eficaz que el ácido acetilsalicílico en la prevención de accidentes cerebrovasculares en pacientes con fibrilación auricular. También se estudiará la seguridad de este tratamiento.

Descripción detallada

Se proporcionará una fase de extensión abierta a largo plazo opcional con apixabán para los participantes que califiquen, tras la conclusión de la fase doble ciego.

Elegibilidad

Edad mínima: 50 YearsSexo: ALL

Criterios de inclusión

Male and female
Age of 50 years or older
Permanent, paroxysmal, or persistent atrial fibrillation (at screening or within 6 months prior to enrollment) documented by 12-lead electrocardiogram)
At least 1 of the following risk factors for stroke:
Prior stroke or transient ischemic attack
Age of 75 years or older
Arterial hypertension on treatment
Diabetes mellitus
Heart failure (New York Health Authority Class 2 or greater at time of enrollment)
Left ventricular ejection fraction of 35% or less, documented within 6 months of enrollment
Peripheral arterial disease (previous arterial revascularization, limb or foot amputation, or current intermittent claudication with ankle-arm systolic blood pressure ratio \<0.9)
Not currently receiving vitamin K antagonist therapy for 1 of the following reasons:
Previous vitamin K antagonist therapy demonstrated as unsuitable and discontinued
Vitamin K antagonist therapy not previously used but expected unsuitable

Criterios de exclusión

Women who are pregnant or breast feeding
Women of child bearing potential who are unwilling to meet the study requirements for pregnancy testing or are unwilling or unable to use an acceptable method to avoid pregnancy
Atrial fibrillation due to reversible causes, such as thyrotoxicosis or pericarditis
Valvular disease requiring surgery
Planned ablation procedure for atrial fibrillation to be performed within 3 months
Conditions other than atrial fibrillation that require chronic anticoagulation (such as, prosthetic mechanical heart valve, venous thromboembolism)
Patients with serious bleeding in the last 6 months or at high risk for bleeding, including but not limited to those with:
Active peptic ulcer disease
Platelet count \<100,000/mm\^3 or hemoglobin \<10g/dL
Recent stroke (within 10 days)
Documented hemorrhagic tendencies or blood dyscrasias
Current alcohol or drug abuse or psychosocial reasons that make study participation impractical
Severe comorbid condition with life expectancy \<1 year
Severe renal insufficiency; any patient with a serum creatinine level \>2.5 mg/dL or a calculated creatinine clearance \<25 mL/min is excluded
Alanine transaminase or aspartate aminotransferase levels \>2 times upper limit of normal (ULN) or a total bilirubin level \>1.5 times ULN (unless an alternative causative factor \[such as Gilbert's syndrome\] is identified)
Allergy or adverse reaction to acetylsalicylic acid
Required treatment with a thienopyridine (clopidogrel or ticlopidine)
Prisoners or participants who are compulsory detained (involuntarily incarcerated)
Use of an investigational drug or device within the past 30 days or prior randomization into an apixaban clinical study
Patients who are compulsorily detained for treatment for a psychiatric or physical illness

Intervenciones

drug

Apixaban

Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks

drug

Acetylsalicylic acid

Tablets, oral, 81-324 mg, once daily, up to 156 weeks

Ubicaciones

Local Institution

Adrogué, Buenos Aires, Argentina

Local Institution

Autonoma Buenos Aires, Buenos Aires, Argentina

Local Institution

Bahía Blanca, Buenos Aires, Argentina

Local Institution

Coronel Suárez, Buenos Aires, Argentina

Local Institution

Haedo, Buenos Aires, Argentina

Local Institution

La Plata, Buenos Aires, Argentina

Local Institution

La Plata, Buenos Aires, Argentina

Local Institution

Mar del Plata, Buenos Aires, Argentina

Local Institution

Merlo, Buenos Aires, Argentina

Local Institution

Ramos Mejía, Buenos Aires, Argentina

Local Institution

San Francisco, Córdoba Province, Argentina

Local Institution

San Salvador de Jujuy, Jujuy Province, Argentina

Local Institution

Zárate, Provincia Buenos Aires, Argentina

Local Institution

Rosario, Santa Fe Province, Argentina

Local Institution

Rosario, Santa Fe Province, Argentina

Local Institution

Rosario, Santa Fe Province, Argentina

Local Institution

San Miguel de Tucumán, Tucumán Province, Argentina

Local Institution

San Miguel de Tucumán, Tucumán Province, Argentina

Local Institution

Buenos Aires, Argentina

Local Institution

Corrientes, Argentina

Local Institution

Córdoba, Argentina

Local Institution

Córdoba, Argentina

Local Institution

Córdoba, Argentina

Local Institution

Córdoba, Argentina

Local Institution

Córdoba, Argentina

Local Institution

Córdoba, Argentina

Local Institution

Salta, Argentina

Local Institution

Santa Fe, Argentina

Apixabán versus ácido acetilsalicílico (AAS) para prevenir el accidente cerebrovascular en pacientes con fibrilación auricular que han fracasado o no son aptos para el tratamiento con antagonistas de la vitamina K: ensayo aleatorizado doble ciego

Resumen

Descripción detallada

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

Apixaban

Acetylsalicylic acid

Ubicaciones

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Patrocinadores